Researchclopedia

Research Researchers Institutions Topics Submit About

Command Palette

Search for a command to run...

Researchclopedia

Research Researchers Institutions About

© 2026 Researchclopedia. Powered by OpenAlex under CC0 license.

Ability Pharmaceuticals (Spain) | Researchclopedia

Back to institutions

Ability Pharmaceuticals (Spain)

Barcelonacompany

33

Works

1,801

Citations

24

h-index

Top Research Topics

Autophagy in Disease and Therapy Endoplasmic Reticulum Stress and Disease PI3K/AKT/mTOR signaling in cancer

Top Researchers

Per Gustafson Ability Pharmaceuticals (Spain)

141 works8,639 citationsh-index: 49

Recent Research

From bench to bedside: ABTL0812 and immunotherapy as a breakthrough strategy for neuroblastoma (was selected for Fire-session)

M.J. Pérez-Garcia,L. Valero,et al.

20260 citations

Cancer, Hypoxia, and Metabolism

Histone Deacetylase Inhibitors Research

Cancer-related gene regulation

Ovarian cancer diagnosis and treatment

Endometrial and Cervical Cancer Treatments

HER2/EGFR in Cancer Research

Monoclonal and Polyclonal Antibodies Research

Ubiquitin and proteasome pathways

Cholangiocarcinoma and Gallbladder Cancer Studies

Jordi Espadaler Kaneka (United States)

84 works1,898 citationsh-index: 23

Marc Yeste‐Velasco Ability Pharmaceuticals (Spain)

45 works1,206 citationsh-index: 20

Paula Muñoz University of Manchester

35 works1,097 citationsh-index: 16

12 works809 citationsh-index: 8

José Alfón Ability Pharmaceuticals (Spain)

59 works794 citationsh-index: 13

KRAS-targeted therapies in colorectal cancer: a systematic analysis of mutations, inhibitors, and clinical trials

Maria Navarro-Jiménez,Beatríz González,et al.

20254 citations

Inflammation, lung function, symptoms and reliever use in chronic obstructive pulmonary disease

Richard Russell,Graham W. Clarke,et al.

20250 citations

Understanding Ibrilatazar’s mechanism of action: Addressing concerns about autophagy in cancer Therapy

Joaquim Bosch‐Barrera,Héctor Perez‐Montoyo,et al.

20250 citations

ENDOLUNG trial, part II. A phase II study of the Akt/mTOR inhibitor and autophagy inducer ibrilatazar (ABTL0812) in combination with paclitaxel/carboplatin in patients with squamous non-small cell lung cancer

Joaquim Bosch‐Barrera,Purificación Estévez-García,et al.

20255 citations

Corrigendum: Anticancer effects of ABTL0812, a clinical stage drug inducer of autophagy-mediated cancer cell death, in glioblastoma models

A. Mancini,Alessandro Colapietro,et al.

20250 citations